在门置换之前,Empagliflozin在心力衰竭中具有严重的大动脉狭窄的作用:EASTER-HF研究
Pankaj Jariwala1, Gururaj Pramod Kulkarni1, Arshad Punjani2
1Department of Cardiology, Yashoda Hospitals, Somajiguda, Raj Bhavan Road, Hyderabad, Telangana, 500082, India.
Indian heart journal
|June 15, 2024
概括
在阿动脉置换之前,empagliflozin显著减少了严重大动脉狭窄和心力衰竭的患者的心力衰竭死亡或住院治疗的73%. 这种治疗还改善了射出分数,降低了死亡风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的退行性大动脉狭窄症 (DAS) 通常与心力衰竭 (HF) 一起存在.
- 大动脉置换 (AVR) 是严重DAS的标准治疗方法,但HF可能会使结果复杂化.
- 在AVR之前,在这些患者中有效管理HF至关重要.
研究的目的:
- 在AVR之前评估empagliflozin在患有严重DAS和HF的患者中的疗效.
- 评估empagliflozin对HF相关事件和死亡率的影响.
主要方法:
- 这是一项前性研究,涉及20名患有严重DAS,HF (LVEF30-80%) 和NYHAII-IV类症状的患者.
- 患者在AVR发生前6个月内接受了empagliflozin (10mg) 加标准护理 (SOC) 或单独的SOC.
- 监测了包括HF死亡,HF (HHF),LVEF和NT-proBNP水平在内的结果.
主要成果:
- 在6个月后,将empagliflozin添加到SOC中,使HF死亡或HHF减少了73% (RR 0.27;p=0.022).
- 恩帕格利弗洛辛显著改善左心室喷射分数 (LVEF) +3.48% (p < 0.001).
- 观察到NT-proBNP水平显著降低 (-3974.6 pg/mL),并减少住院和6个月死亡率.
结论:
- 当添加到SOC时,empagliflozin对接受AVR的严重DAS和HF患者显示出显著的益处.
- 该药物改善了心脏功能,减少了HF事件,并降低了这种高风险人群的死亡率.
- 恩帕格利弗洛辛代表了一种有前途的治疗选择,可以改善患有同时存在严重DAS和HF的患者的治疗结果.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K